Altimmune, Inc. · NASDAQ:ALT
Altimmune — Technical Presentation (November 2026)
16 slides from Altimmune's technical presentation, Nov 7, 2026
Slide 1: Pemvidutide Treatment Reduces Alcohol Intake in a Lean Golden Syrian Hamster Model
Pemvidutide Treatment Reduces Alcohol Intake in a Lean Golden Syrian Hamster Model Maynara L. Andrade,1 John J. Suschak,1 Francois Briand,2 M. Scot Roberts1 1Altimmune, Inc, Gaithersburg, MD, USA; 2Physiogenex, Escalquens, France Abstract 0173 | November 7, 2026; 8:15 am
Slide 2: Please Do Not Take Pictures
Please Do Not Take Pictures Slides are the property of the authors and AASLD. Permission is required from both AASLD and the author for reuse.
Slide 3: Disclosures
Disclosures Dr. Suschak’s Disclosures Employment: Altimmune, Inc Stock / Shareholding: Altimmune, Inc. Patents: U.S. Army and Altimmune, Inc. Disclaimer: This presentation discusses pemvidutide, an investigational product candidate that has not been approved by the FDA or any other regulatory author
Slide 4: Prevalence of Alcohol Use Disorder
Alcohol Use Disorder (AUD) • Affects approximately 28M people in the United States.a AUD Prevalence and Pharmacological Treatment 3×10 7 27.9M • Up to 90% of patients with AUD develop liver steatosisb 2.5×10 7 • Many patients with AUD progress to more severe 2×10 7 alcohol-associated liver disease (
Slide 5: Effects of GLP-1 Receptor Agonists on AUD
Effects of GLP-1 Receptor Agonists on AUD Significant reductions in consumption, reward-processing, and relapse-like behavior • There is growing real world evidence that GLP-1 receptor agonists reduce alcohol consumption Reward Pathways Consumption • There are relatively few randomized, placebo-cont
Slide 6: Pemvidutide May Treat Both AUD and ALD
Pemvidutide, a Glucagon/GLP-1 Dual Receptor Agonist, May Treat Both AUD and ALD May Address Both the Behavioral and Hepatic Drivers of Disease Potential Outcomes Direct Significant reductions in alcohol Reward Pathways consumption Effects on Liver Consumption Glucagon Cravings Improvements in live
Slide 7: Balanced 1:1 Glucagon/GLP-1 Dual Receptor Agonist
Balanced 1:1 Glucagon/GLP-1 Dual Receptor Agonist Delayed Tmax with lower Cmax Better Tolerability COOH EC50 (picomolar)a Ligand Human Human EuPort Pemvidutide (CH2)n Domain GLP-1R GCGR Glucagon -- 68 GLP-1 15 -- Pemvidutide 39 42 Semaglutide 15 -- Glucagon specificity GLP-1 specificity Glucagon G
Slide 8: Study Design
Study Design Three-Week Treatment Phase 15% Alcohol Induction Period Treatment Period -28 0 20 Treatment Group # Animals Treatment Route Dose Frequency 1 12 vehicle subcutaneous 1 x Daily -- 2 12 pemvidutide subcutaneous 1 x Daily 10nmol/kg Slides are the property of the authors and AASLD. Permissio
Slide 9: Alcohol Intake Increased During the Induction Phase
Alcohol Intake Increased During the Induction Phase Hamsters Favored Alcohol Over Water by End of Induction Phase Fluid Intake During Induction Phase 12 water 15% alcohol 11 • Hamsters developed a significant 10 preference for alcohol 9 ** Mean Fluid Intake (mL ± SE) 8 7 • Alcohol intake steadily in
Slide 10: Pemvidutide Treatment Resulted in Significantly Decreased Alcohol Intake
Pemvidutide Treatment Resulted in Significantly Decreased Alcohol Intake Maximal reduction in alcohol intake of ~80% from treatment initiation Alcohol Intake as Percentage of Total Fluid Intake 100 vehicle Mean % Alcohol Intake per Day [mL Alcohol / (mL Alcohol + mL Tap Water)] pemvidutide 90 80 70
Slide 11: Pemvidutide Alters Expression of Genes in Alcohol Metabolism and Hepatocyte Survival
Pemvidutide Treatment Alters the Expression of Genes Involved in Alcohol Metabolism and Hepatocyte Survival RT-qPCR Aldehyde Dehydrogenase 1 Cytochrome P450 2E1 Caspase-3 (Aldh1) (Cyp2E1) (Casp3) 2.5 ✱✱✱✱ 2.5 2.5 2.1 • Aldh1 metabolizes toxic alcohol byproducts 2.0 2.0 2.0 (Fold Change vs. Vehicle)
Slide 12: Pemvidutide Alters Expression of Genes Regulating Hepatic Lipid Metabolism
Pemvidutide Treatment Alters the Expression of Genes Regulating Hepatic Lipid Metabolism RT-qPCR Acetyl-CoA Carboxylase 1 Stearoyl-CoA Desaturase Carnitine Palmitoyltransferase 1A (Acca) (Scd1) (Cpt1a) 3.0 3.0 3.0 ✱✱ • Acca drives fatty acid 2.5 2.5 2.5 synthesis 2.0 (Fold Change vs. Vehicle) (Fold
Slide 13: Pemvidutide Treatment Resulted in Significant Weight Loss
Pemvidutide Treatment Resulted in Significant Weight Loss Weight Change Weight Change at Day 20 20 vehicle 15 Mean Relative Change from Baseline (% ± SE) ✱✱✱✱ pemvidutide Mean Relative Change from Baseline (% ± SE) 15 10 7.2% 10 5 5 0 0 -5 -5 -10 -10 -15 -15 **** -14.1% -20 0 2 4 6 8 10 12 14 16 18
Slide 14: Summary
Summary • Pemvidutide treatment significantly reduced alcohol intake in a preclinical hamster model of AUD • Pemvidutide treatment significantly increased the expression of genes involved in hepatic alcohol metabolism and decreased the expression of the pro-apoptotic gene caspase-3 in the liver • Pe
Slide 15: RECLAIM Phase 2 Clinical Trial in AUD Topline Results
RECLAIM Phase 2 Clinical Trial in AUD Topline Results Efficacy and Safety of Pemvidutide in the Treatment of Adults with Alcohol Use Disorder: Results from RECLAIM, a 24-Week Phase 2 Randomized Double-Blind Placebo-Controlled Trial Henry R. Kranzler,1 Shaheen Tomah,2 W. Kyle Simmons,3 Stephanie S. O
Slide 16: Thank You
Thank You AASLD